Sana Biotechnology, Inc. (NASDAQ:SANA – Get Rating) major shareholder Ventures Fund V. Gener Flagship sold 347,870 shares of the firm’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $6.57, for a total transaction of $2,285,505.90. Following the transaction, the insider now directly owns 1,447,791 shares in the company, valued at $9,511,986.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
Sana Biotechnology Stock Performance
SANA stock traded up $0.04 during mid-day trading on Friday, hitting $6.28. The company had a trading volume of 1,094,503 shares, compared to its average volume of 1,201,326. The firm has a market cap of $1.20 billion, a PE ratio of -3.64 and a beta of 0.71. Sana Biotechnology, Inc. has a 12 month low of $2.99 and a 12 month high of $9.55. The stock’s fifty day moving average price is $4.98 and its two-hundred day moving average price is $4.51.
Sana Biotechnology (NASDAQ:SANA – Get Rating) last announced its quarterly earnings data on Thursday, March 16th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.01. Equities analysts anticipate that Sana Biotechnology, Inc. will post -1.49 earnings per share for the current year.
Hedge Funds Weigh In On Sana Biotechnology
Analyst Upgrades and Downgrades
A number of research analysts recently weighed in on the stock. HC Wainwright assumed coverage on shares of Sana Biotechnology in a research report on Tuesday, May 2nd. They set a “neutral” rating on the stock. Bank of America lowered their price objective on shares of Sana Biotechnology from $13.00 to $11.00 in a research report on Friday, March 17th.
Sana Biotechnology Company Profile
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others.
- Get a free copy of the StockNews.com research report on Sana Biotechnology (SANA)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.